Radiopharmaceuticals with high stability and radiolabeling efficiency and theranostic kit comprising said radiopharmaceuticals

EP4522229A1Pending Publication Date: 2025-03-19CURIUM NUEKLEER TIP ANONIM SIRKETI +1
0 Cites 0 Cited by

Patent Information

Application Number
EP2022941821
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-05-13
Filing Date
2022-05-31
Publication Date
2025-03-19

AI Technical Summary

Technical Problem

Current methods for diagnosing and treating HER2-positive cancers are invasive, inaccurate, and lead to primary resistance, with conventional radiopharmaceuticals having low stability and radiolabeling efficiency, which complicates the detection and destruction of cancer cells without damaging healthy tissues.

Method used

Development of radiopharmaceuticals comprising the monoclonal antibody Trastuzumab conjugated with the chelating agent mercapto acetyl triglycine-3 (MAG3) and radionuclides like Ga-68 or Lu-177, enabling high stability and radiolabeling efficiency for non-invasive imaging and targeted destruction of cancer cells, with the option of a theranostic kit for easy storage and use.

Benefits of technology

The radiopharmaceuticals provide reliable detection and efficient destruction of HER2-positive and HER2-negative cancer cells with minimal healthy tissue damage, reducing treatment side effects and costs, while maintaining high stability and radiolabeling efficiency throughout the radionuclide's half-life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The subject of the invention relates to the radiopharmaceuticals with high stability and radiolabeling efficiency obtained by attaching a radionuclide to a pharmaceutical part with high stability that is obtained by attaching a chelating agent to a pharmaceutical specific to the receptors present in the tumor area, said radiopharmaceuticals enabling the imaging and / or the destruction of the cancer cells, to a method for obtaining said radiopharmaceuticals and to a kit comprising said radiopharmaceuticals. The radiopharmaceuticals according to the invention basically comprise at least one radionuclide, which enables the imaging and / or the destruction of the cancer cells, at least one pharmaceutical part, which includes at least one pharmaceutical agent targeting the receptor that causes the growth of the cancer cells, at least one chelating agent enabling at least one radionuclide to be attached to said pharmaceutical agent.
Need to check novelty before this filing date? Find Prior Art